met kinase inhibitors (Bristol-Myers Squibb)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namemet kinase inhibitors (Bristol-Myers Squibb)
Drug Alias Namec-met receptor tyrosine kinase inhibitors (BMS)hepatocyte growth factor receptor inhibitors (BMS)BMS-698769BMS-738533BMS-733015
ClassificationSmall molecules
Mechanisms of ActionHepatocyte growth factor receptor inhibitorsAnticancer protein kinase inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A